European Respiratory Society short guidelines for the use of as-needed ICS/formoterol in mild asthma
Recent clinical trials of as-needed fixed-dose combination of inhaled corticosteroid (ICS)/formoterol have provided new evidence that may warrant a reconsideration of current practice. A Task Force was set up by the European Respiratory Society to provide evidence-based recommendations on the use of as-needed ICS/formoterol as treatment for mild asthma. The Task Force defined two questions that were assessed using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach. The Task Force utilised the outcomes to develop recommendations for a pragmatic guideline for... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2023 |
Schlagwörter: | Fixed-dose combination of inhaled corticosteroid (ICS)/formoterol / mild asthma / clinical trial / short-acting β2-antagonist (SABA) / systemic corticosteroid / exacerbations |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26879229 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://hdl.handle.net/11392/2525452 |